Navigation Links
Clinical Site Services' Chris Trizna Contributing Author in Diana Anderson-Foster's Newest Release 'Global Issues in Patient Recruitment and Retention'
Date:7/17/2012

GLEN BURNIE, Md., July 17, 2012 /PRNewswire/ -- Chris Trizna, President of Clinical Site Services (CSS), a Maryland company focused on optimizing and accelerating the trial enrollment process for sponsor companies, CROs and investigative sites, is included as a contributing author in Diana Anderson-Foster's newest book, "Global Issues in Patient Recruitment and Retention," published in June 2012 by CenterWatch.

It is well-documented that slow patient enrollment is a global contributor of study delays. Likewise, retaining patients once enrolled can be equally arduous, but just as critical to the completion and success of a clinical trial. In her second book on the subject, industry expert Diana Anderson-Foster tackles for the first time the global challenges posed by these everyday issues and provides thoughtful analysis and strategic solutions to minimize recruitment costs and develop successful global patient recruitment programs. With insight and contributions from thought-leaders in the industry, this guide also delves into the sponsor's perspective on patient recruitment and tackles new emerging topics including technology challenges, phase I recruiting and the role of social media.

"It was a honor to be able to contribute to this book," shared Trizna. "As individuals in the pharmaceutical industry are finding out, global planning for recruitment and retention is a very complex process. Diana's book provides a thorough breakdown of how to approach and find success where global trials are involved."

"Working with global clinical trials requires more than simply providing translation services for each country's recruitment materials," added Trizna. "There is a complex strategy to everything, and it begins with careful planning, research and budgeting."

For more information about "Global Issues in Patient Recruitment and Retention," please visit https://store.centerwatch.com/p-311-global-issues-in-patient-recruitment-and-retention.aspx.

For quantity book orders, please direct the inquiries to sales@centerwatch.com.

About Clinical Site Services

Clinical Site Services (CSS) is a site performance company that provides solutions to increase the enrollment potential for investigative sites. Through a proprietary, integrated process, CSS strives to reduce the costs and timelines associated with recruitment subjects for clinical studies.

For More Information

Visit www.ClinicalSiteServices.com, or contact Jennifer Whitlock, Vice President, at jwhitlock@clinicalsiteservices.com or 443-308-5803.

Contact:

Jennifer Whitlock
Clinical Site Services
P: 443-308-5803
F: 410-553-0087
jwhitlock@clinicalsiteservices.com
www.clinicalsiteservices.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Clinical Site Services
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ERT Granted Patents on Clinical Trial Participant Compliance
2. Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology for Proteomic Applications in Research, Applied and Clinical Markets
3. Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market - Global Trends, Challenges, Opportunities & Forecasts (2012 - 2017)
4. Beyond Batten Disease Foundation and American Brain Foundation Launch First Clinical Research Fellowship to Treat and Cure Juvenile Batten Disease
5. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Agility Clinical, Inc., a Specialty Contract Research Organization is Formed
9. Novocureā„¢ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
10. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
11. OrbusNeichs Combo Dual Therapy Stentā„¢ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Champions Oncology, Inc. (NASDAQ: CSBR ), a ... technology solutions and products to personalize the development and ... new cohorts of PDX models to their existing TumorBank. ... product line in hepatocellular cancer, breast cancer, castrate resistant ... cell lung cancer (including EGFR mutation; ALK/ROS1 positive) PDX ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... , Feb. 16, 2017 Paradigm Diagnostics ... B financing, adding an additional $3M from New Sciences ... Verde Venture Partners and other strategic partners at the ... further accelerating commercial adoption of their flagship Paradigm Cancer ... expanding the Paradigm cancer registry. Dr. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):